<DOC>
	<DOCNO>NCT01371578</DOCNO>
	<brief_summary>This Phase 2b , Randomized , Double-Blind , Placebo-Controlled Trial Evaluating Response Guided Therapy use Combinations Oral Antivirals ( GS-5885 , tegobuvir , and/or GS-9451 ) Peginterferon Alfa 2a Ribavirin Treatment Experienced Subjects Chronic Genotype 1 Hepatitis C Virus ( HCV ) Infection .</brief_summary>
	<brief_title>Oral Antivirals ( GS-5885 , Tegobuvir , and/or GS-9451 ) With Peginterferon Alfa 2a Ribavirin Treatment Experienced Subjects With Chronic Genotype 1 Hepatitis C Virus Infection</brief_title>
	<detailed_description>In September 2011 , FDA request Gilead make several major change study side effect experience two patient Gilead study . In 2 HCV-infected people give tegobuvir another experimental medication plus interferon ribavirin , big reduction number white blood cell , red blood cell platelet see . Because case might relate tegobuvir give interferon , ribavirin another direct antiviral agent , tegobuvir longer give people medication study . As result , study open label mean study doctor know medication receive Arms 1 3 discontinue study . All subject enrol study September 2nd 2011 receive Response Guided Therapy ( RGT ) GS-5885 GS-9451 plus PEG RBV .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Antiviral Agents</mesh_term>
	<mesh_term>Ledipasvir</mesh_term>
	<criteria>Male female , age 18 70 year old , inclusive Chronic HCV infection least 6 month prior Baseline Subjects must liver biopsy result ( ≤ 3 year prior screen ) indicate absence cirrhosis . Monoinfection HCV genotype 1 HCV RNA &gt; 10^4 IU/mL Screening Prior treatment adherence ( defined receive least 80 % prescribed treatment ) one course pegylated interferonalfa ( Pegasys PegIntron ) RBV The subject 's medical record must include sufficient detail prior treatment pegylated interferonalfa RBV ( start/stop date viral response ) allow categorization prior response either NonResponder : Subject achieve undetectable HCV RNA level end treatment period least 12 week duration . Within Nonresponders , subject define Null Partial Responders &lt; 2 log10 ≥ 2 log10 reduction , respectively , HCV RNA first 12 week treatment Responder : Subject achieve undetectable HCV RNA treatment . Within Responders , subject define Relapsers undetectable HCV RNA end least 42 week treatment detectable HCV RNA level observe within 1 year end treatment Breakthrough subject achieve undetectable HCV RNA level treatment period detectable HCV RNA end treatment . No prior treatment oral HCV antiviral ( exclusive RBV ) . Body mass index ( BMI ) 1836 kg/m2 , inclusive . Screening ECG without clinically significant abnormality QTcF interval ( QT correct use Fridericia 's formula ) ≤ 450 msec male ≤ 470 msec female Creatinine clearance ≥ 50 mL/min . Agree use two form highly effective contraception duration study 6 month last dose study medication . Females childbearing potential must negative pregnancy test Screening Baseline Discontinued prior treatment pegylated interferonalfa RBV due adverse event , toxicity reason lose followup . Exceed define threshold leukopenia , neutropenia , anemia , thrombocytopenia , thyroid stimulate hormone ( TSH ) Diagnosis autoimmune disease , decompensated liver disease , poorly control diabetes mellitus , significant psychiatric illness , severe chronic obstructive pulmonary disease ( COPD ) , HIV , hepatitis B virus ( HBV ) , another HCV genotype , hepatocellular carcinoma malignancy ( exception certain skin cancer ) , hemoglobinopathy , retinal disease , immunosuppressed . Current use amphetamine , cocaine , opiate ( e.g. , morphine , heroin ) , ongoing alcohol abuse exclude . Subjects stable methadone exclude , however stable buprenorphine maintenance treatment least 6 month exclusionary Receiving prohibit concomitant medication .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Hepatitis C</keyword>
	<keyword>HCV</keyword>
	<keyword>Rapid Virologic Response</keyword>
	<keyword>Sustained Virologic Response</keyword>
	<keyword>Direct Acting Antiviral</keyword>
	<keyword>Combination Therapy HCV RNA</keyword>
	<keyword>Polymerase inhibitor</keyword>
	<keyword>Protease inhibitor</keyword>
	<keyword>Treatment naïve</keyword>
	<keyword>GS-5885</keyword>
	<keyword>GS-9190</keyword>
	<keyword>Tegobuvir</keyword>
	<keyword>GS-9451</keyword>
</DOC>